Jefferies Upgrades Onyx Pharmaceuticals (ONXX) to Buy; FDA Approves Kyprolis; Takeover Speculation Intensifies
Tweet Send to a Friend
Get Alerts ONXX Hot Sheet
Price: $96.29 +3.50%
Rating Summary:
20 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 29
Rating Summary:
20 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 29
Trade ONXX Now!
Jefferies upgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Hold to Buy with a price target of $101.00 (from $55.00).
Analyst, Biren Amin, said, "Kyprolis (carfilzomib) received FDA approval for RRMM a week ahead of its PDUFA date with an in-line label. With improved Kyprolis commercial outlook driven by better-than-expected pricing and limited near-term downside, we are upgrading ONXX to Buy..." (FY14 EPS estimate raised from (1.20) to $0.57)
"With the intensifying takeout speculation on ONXX, we performed a M&A analysis showing ONXX could offer a $7.5B gain in EV (NewCo v acquirer on DCF), supporting a takeout price of ~$122/shr (a ~61% premium to the current $76/shr valuation and ~21% upside to our $101 PT). Our analysis uses Bayer as a “template acquirer” but there may be upside to EV gain for other potential acquirers with a larger heme/onc presence (e.g. Novartis (NYSE: NVS)(Buy) on improved synergies."
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $76.38 yesterday, with a 52 week range of $27.17-$79.20.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Biren Amin, said, "Kyprolis (carfilzomib) received FDA approval for RRMM a week ahead of its PDUFA date with an in-line label. With improved Kyprolis commercial outlook driven by better-than-expected pricing and limited near-term downside, we are upgrading ONXX to Buy..." (FY14 EPS estimate raised from (1.20) to $0.57)
"With the intensifying takeout speculation on ONXX, we performed a M&A analysis showing ONXX could offer a $7.5B gain in EV (NewCo v acquirer on DCF), supporting a takeout price of ~$122/shr (a ~61% premium to the current $76/shr valuation and ~21% upside to our $101 PT). Our analysis uses Bayer as a “template acquirer” but there may be upside to EV gain for other potential acquirers with a larger heme/onc presence (e.g. Novartis (NYSE: NVS)(Buy) on improved synergies."
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $76.38 yesterday, with a 52 week range of $27.17-$79.20.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Jefferies Raises Numbers on hhgregg (HGG), But Remains on Sidelines
- NetApp (NTAP) Post Solid Q4, Numbers Bumped - Needham & Company
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, FDA, Rumors, UpgradesRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
